



20

1362

PATENT  
Docket No.: 20011/1371

#  
11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beck et al.  
Serial No. : 09/704,306  
Cnfrm. No. : 4919  
Filed : November 2, 2000

Examiner:  
To Be Assigned

Art Unit:  
1362

For : NOVEL 4-PHENYL SUBSTITUTED  
TETRAHYDROISOQUINOLINES AND USE  
THEREOF

TECH CENTER 1600/2900

JUN 0 5 2002

JUN 0 7 2002

RECEIVED

RECEIVED

REVOCATION AND POWER OF ATTORNEY

U.S. Patent and Trademark Office  
Box 2327  
Arlington, Virginia 22202  
Box:

Dear Sir:

The undersigned assignee of the entire interest in the above-identified application for Letters Patent, **Albany Molecular Research, Inc.**, hereby revokes all previous powers of attorney in the subject application and hereby appoints Michael L. Goldman, Registration No. 30,727; Joseph M. Noto, Registration No. 32,163; Gunnar G. Leinberg, Registration No. 35,584; Edwin V. Merkel, Registration No. 40,087; Georgia Evans, Registration No. 44,597; Alice Y. Choi, Registration No. 45,758; Andrew K. Gonsalves, Registration No. 48,145; Noreen L. Connolly, Registration No. 48,987; and John Campa, Registration No. 49,014 all with a mailing address of Nixon Peabody LLP, Clinton Square, P.O. Box 31051, Rochester, New York 14603, telephone number (585) 263-1000, as its attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected herewith.

The undersigned assignee of the right, title and interest of the above-identified application, hereby confirms that an assignment from the inventors to DuPont

Pharmaceuticals Company for the subject application was recorded on **May 21, 2001**, at Reel **011831/Frame 0728** in the U.S. Patent and Trademark Office. A Change of Name Recordation from DuPont Pharmaceuticals Company to Bristol-Myers Squibb Pharma Company (copy enclosed) was filed on January 8, 2002. An assignment from Bristol-Myers Squibb Pharma Company to Albany Molecular Research, Inc. (copy enclosed) was filed with the U.S. Patent and Trademark Office on May 16, 2002.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of the undersigned's knowledge and belief, title is in the assignee identified below.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please direct all future communications relative to said application to the following correspondence address:

Michael L. Goldman  
NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (585) 263-1304  
Facsimile: (585) 263-1600


Respectfully submitted,

ALBANY MOLECULAR RESEARCH, INC.

Dated: May 20, 2002

By: Lawrence C. Jones  
Lawrence C. Jones, Ph.D.

Albany Molecular Research, Inc.  
21 Corporate Circle  
P.O. Box 15098  
Albany, New York 12212-5098  
Telephone: (518) 464-0279  
Facsimile: (518) 464-0289



TECH CENTER 1600/2900

JUN 07 2002

RECORDATION FORM COVER SHEET PATENTS ONLY		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
Form PT-1595 (TRADE/101) OMB No. 0651-0027 (exp. 5/31/2002) Tab settings ⇌ ⇌ ⇌ ▼ ▼ ▼ ▼ ▼ ▼ ▼ ▼			
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.			
<b>1. Name of conveying party(ies):</b> DuPont Pharmaceuticals Company		<b>2. Name and address of receiving party(ies)</b> Name: Bristol-Myers Squibb Pharma Company Internal Address: Patent Department Street Address: P.O. Box 4000 City: Princeton State: NJ Zip: 08543-4000	
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		RECEIVED JUN 05 2002 TECH CENTER 1600/2900	
<b>3. Nature of conveyance:</b> <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Change of Name <input type="checkbox"/> Other _____ Execution Date: 10/01/2001			
<b>4. Application number(s) or patent number(s):</b> If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) _____ See Schedule B attached B. Patent No.(s) _____ See Schedule A attached Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No			
<b>5. Name and address of party to whom correspondence concerning document should be mailed:</b> Name: Denise Bierlein Internal Address: E353/133F Experimental Station Street Address: Route 141 & Henry Clay Road City: Wilmington State: DE Zip: 19880-0353		<b>6. Total number of applications and patents involved:</b> 614 <b>7. Total fee (37 CFR 3.41).....\$</b> 24,560.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account <b>8. Deposit account number:</b> 023850	
<b>DO NOT USE THIS SPACE</b>			
<b>9. Signature.</b> Denise M. Bierlein Name of Person Signing <i>Denise M. Bierlein</i> Signature January 8, 2002 Date Total number of pages including cover sheet, attachments, and documents: 17			

Mail documents to be recorded with required cover sheet information to:  
Commissioner of Patents & Trademarks, Box Assignments  
Washington, D.C. 20231

**RECEIVED**

JUN 07 2002

**PATENT****TECH CENTER 1600/2900****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****CHANGE OF NAME IN RECORDED ASSIGNMENTS****RECEIVED**

JUN 05 2002

**TECH CENTER 1600/2900****1. Particulars of assignments**

A list of the patent applications and patents for which the change of name in the recorded assignment is requested is set forth in Schedule A (granted patents) and Schedule B (pending patent applications) attached hereto.

**2. Old name of assignee**

The old name of the assignee shown on the above-referenced assignments is DuPont Pharmaceuticals Company.

**3. New name and address of assignee**


The new name of the assignee is Bristol-Myers Squibb Pharma Company located at the following address: Patent Department, P.O. Box 4000, Princeton, NJ 08543-4000.

**4. Proof of change of name**

Proof of change of name is established by the attached certificate of name change from the following authority: Supplemental Certificate - New Castle County, Delaware

**5. Payment of fee**

Please refer to the RECORDATION FORM COVER SHEET, to which this paper is attached.

  
Blair Q. Ferguson  
Reg. No. 34,329  
Counsel, Intellectual Property  
Experimental Station, E353/133C  
Route 141 and Henry Clay Road  
Wilmington, DE 19880-0353  
Phone: 302/695-3902

SUPPLEMENTAL CERTIFICATE  
NEW CASTLE COUNTY.  
REGISTRATION OF TRADE NAMES  
PARTNERSHIPS & ASSOCIATIONS

6 Del C. Ch. 31

TRADE NAME: Bristol-Myers Squibb Pharma Company (Original File No. 25757.0)

Business Address: 203 Longmeadow Drive, Wilmington, DE 19810

Telephone Number: \_\_\_\_\_

Title of Person, Firm or Association: Bristol-Myers Squibb Pharma Company

Names and addresses of all owners, members, or partners comprising the firm:

LAST NAME	FIRST NAME	ADDRESS
E.R. Squibb & Sons, L.L.C.		345 Park Ave., New York, NY 10154
Bristol-Myers Squibb Pharma Holding Company, LLC		345 Park Ave., New York, NY 10154

Date of <sup>change</sup> formation: October 2, 2001

Nature of <sup>change</sup> Business: Title of partnership has changed from "DuPont Pharmaceutical Company" to "Bristol-Myers Squibb Pharma Company" and the partners have changed from E.I. du Pont de Nemours and Company and DuPont State of Delaware Pharma, Inc. to E.R. Squibb & Sons, L.L.C. and Bristol-Myers Squibb Pharma Holding Company, LLC

Queens NEW CASTLE COUNTY  
BEFORE ME, the subscriber, a Notary Public of the State of Delaware, personally appeared Sandra Leung, Secretary of Bristol-Myers Squibb Pharma Company, a principal in the business described in the foregoing Certificate, who, having first been sworn by me according to law did depose and say as follows:

1. He/She is a principal in the business described in the foregoing certificate.

2. That the foregoing information provided in the foregoing certificate is true, correct, and complete.

[Signature]  
Affiant

SWORN AND SUBSCRIBED this 2<sup>nd</sup> day of October, 2001.

[Signature]  
NOTARY PUBLIC

MAUREEN A. ROOS  
Notary Public, State of New York  
No. 01RO4826850  
Qualified in Queens County  
Commission Expires December 31, 2002

REV: 2/90

CERTIFIED AS A TRUE COPY.  
ATTEST: SHARON AGNEW  
PROTHONOTARY

[Signature]

[illegible]



RECORDATION FORM COVER SHEET  
PATENTS ONLY

RECEIVED

JUN 07 2002

TECH CENTER 1600/2900

To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof:

<p>1. Name of conveying party(ies):</p> <p><b>Bristol-Myers Squibb Pharma Company</b></p>	<p>2. Name and address of receiving party(ies):</p> <p><b>Albany Molecular Research, Inc. 21 Corporate Circle Albany, New York 12203-5154</b></p>
<p>3. Nature of conveyance:</p> <p><input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: _____</p> <p>Execution Date(s): <b>March 15, 2002</b></p> <p>1st (sole) Inventor: 2nd Inventor: 3rd Inventor: 4th Inventor:</p>	<p>RECEIVED</p> <p>JUN 05 2002</p> <p>TECH CENTER 1600/2900</p>
<p>4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date(s) of the application is(are):</p> <p>1st (sole) Inventor: 2nd Inventor: 3rd Inventor: 4th Inventor:</p> <p>A. Patent Application No.(s): <b>09/704,306</b></p> <p>B. Patent No.(s):</p>	

5. Name and address of party to whom correspondence concerning document should be mailed:

**Michael L. Goldman**  
**NIXON PEABODY LLP**  
**Clinton Square**  
**P.O. Box 31051**  
**Rochester, New York 14603-1051**

6. Total number of applications and patents involved: **1**

7. Total fee (37 CFR 3.41): **\$40.00**

☐ Previously paid (see original transmittal)

☒ A check in the amount of **\$40.00** is enclosed.

8. Deposit Account Number: **14-1138**

☐ Charge total fee to account.

☒ Charge any additional fees to account.

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Date: May 16, 2002

Georgia Evans  
**Georgia Evans**  
**Registration No. 44,597**

[Total number of pages including cover sheet, attachments and document: **5**]

Page 2 of 2

**Certificate of Mailing - 37 CFR 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
U.S. Patent and Trademark Office P.O. BOX 2327  
Arlington, VA 22202, on the date below.

Date May 16, 2002 Ruth R. Smith  
Ruth R. Smith



## ATTACHMENT C

PATENT ASSIGNMENT

**WHEREAS**, Bristol-Myers Squibb Pharma Company, a Delaware general partnership ("Assignor"), with its principal place of business at Route 141 and Henry Clay Road, Wilmington, Delaware 19880, U.S.A. is the owner of rights in the patent applications set forth on the attached Schedule 1, and the inventions disclosed and claimed therein (collectively, the "Patent Applications"); and

**WHEREAS**, Albany Molecular Research, Inc., a Delaware corporation ("Assignee"), with its principal place of business at 21 Corporate Circle, Albany, NY 12203-5154, U.S.A., desires to acquire the entire right, title, and interest in and to the Patent Applications;

**WHEREAS**, Assignor and Assignee are parties to a certain License Agreement, entered into as of the date of this assignment (the "License Agreement"), pursuant to which Assignor has agreed to assign to Assignee the Patent Applications;

**NOW, THEREFORE**, for good and valuable consideration, Assignor hereby sells, transfers, assigns, conveys, delivers, and sets over, and by these presents does hereby sell, transfer, assign, convey, deliver, and set over to said Assignee, the entire right, title and interest in and to said Patent Applications and all corresponding rights of priority under the International Convention for the Protection of Industrial Property, the Inter-American Convention Relating to Patent Applications, Designs and Industrial Models, and any other international agreements to which the United States adheres, the same to be held and enjoyed by said Assignee, its successors, assigns, nominees or legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment, sale and transfer not been made;

**AND ASSIGNOR** hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on the Patent Applications to issue to said Assignee, as assignee of the entire right, title and interest, any and all such patents.

**ASSIGNOR** hereby agrees to execute any papers and to perform such other proper acts as Assignee or its successors or assigns may deem reasonably necessary to secure to Assignee or to its successors or assigns, the rights hereby transferred.

**WHEREFORE**, Assignor has caused this Patent Assignment to be duly executed below, on the date indicated, by its duly authorized officer.

**ASSIGNOR:**

Bristol-Myers Squibb Pharma Company

By: *Adam R. S.*Title: *Secretary*Date: *3/15/02*

-----  
Acknowledged and  
Accepted:

**ASSIGNEE:**

Albany Molecular Research, Inc.

By: *Thomas D'Ambra*Name: *Thomas D'Ambra*Title: *CEO**3/15/02*

## SCHEDULE 1

Patent Application No.	Country	Filing Date	BMS Docket No.
60/163,270	U.S.	11/3/99	PH-7032-P1
09/704,306	U.S.	11/2/00	PH-7032/U.S.
US00/30328	PCT	11/3/00	PH-7032/PCT
60/163,269	U.S.	11/3/99	PH-7142-P1
09/704,305	U.S.	11/2/00	PH-7142/U.S.
US00/30329	PCT	11/3/00	PH-7142/PCT
60/217,412	U.S.	7/11/00	PH-7222-P1
09/902,845	U.S.	7/11/01	PH-7222/U.S.
US01/21818	PCT	7/11/01	PH-7222/PCT